HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective Analysis.

AbstractBACKGROUND:
Perivascular epithelioid cell neoplasms (PEComas) are a diverse family of mesenchymal tumors with myomelanocytic differentiation that disproportionately affect women and can be associated with tuberous sclerosis (TS). Although mTOR inhibition is widely used as first-line treatment, it is unclear what genomic alterations exist in these tumors and how they influence the response to therapy.
METHODS:
This was a multicenter study conducted at five sites within the US. The data were collected from 1 January 2004 to 31 January 2021. We conducted a retrospective analysis to identify PEComa patients with next-generation sequencing (NGS) data and compared outcomes based on mutations.
RESULTS:
No significant differences in survival were identified between TSC-1 and TSC-2 mutated PEComa or TSC-1/-2 versus other mutations. No significant difference was seen in progression-free survival (PFS) after first-line therapy between mTOR inhibition versus other systemic therapies.
CONCLUSIONS:
We were unable to detect differences in survival based on genomic alterations or PFS between mTOR inhibition versus other systemic therapies. Future studies should seek to identify other drivers of TSC-1/-2 silencing that could predict response to mTOR inhibition.
AuthorsLawrence Liu, Carina Dehner, Nikhil Grandhi, Yang Lyu, Dana C Borcherding, John S A Chrisinger, Xiao Zhang, Jingqin Luo, Yu Tao, Amanda Parkes, Nam Q Bui, Elizabeth J Davis, Mohammed M Milhem, Varun Monga, Mia Weiss, Brian Van Tine, Angela C Hirbe
JournalGenes (Genes (Basel)) Vol. 13 Issue 11 (10 24 2022) ISSN: 2073-4425 [Electronic] Switzerland
PMID36360169 (Publication Type: Multicenter Study, Journal Article)
Chemical References
  • TOR Serine-Threonine Kinases
Topics
  • Female
  • Humans
  • Mutation
  • Perivascular Epithelioid Cell Neoplasms (genetics, pathology)
  • Retrospective Studies
  • TOR Serine-Threonine Kinases (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: